|
Galidesivir
Galidesivir (BCX4430, immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, flaviviruses, and phleboviruses. Galidesivir has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection, and development for use in humans was then being fast-tracked due to concerns about the lack of treatment options for the 2013-2016 Ebola virus ep ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. History The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of ''Technology Fast 500''. In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change it ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Nucleoside Analog
Nucleoside analogues are structural analogues of a nucleoside, which normally contain a nucleobase and a sugar. Nucleotide analogues are analogues of a nucleotide, which normally has one to three phosphates linked to a nucleoside. Both types of compounds can deviate from what they mimick in a number of ways, as changes can be made to any of the constituent parts (nucleobase, sugar, phosphate). They are related to nucleic acid analogues. Nucleoside and nucleotide analogues can be used in therapeutic drugs, including a range of antiviral products used to prevent viral replication in infected cells. The most commonly used is acyclovir. Nucleotide and nucleoside analogues can also be found naturally. Examples include ddhCTP (3ʹ-deoxy-3′,4ʹdidehydro-CTP) produced by the human antiviral protein viperin and sinefungin (a S-Adenosyl methionine analogue) produced by some ''Streptomyces''. Function These agents can be used against hepatitis B virus, hepatitis C virus, herpes si ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Antiviral Drug
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to pharmacotherapy, treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees. Medical uses Most of the antiviral drugs now available are designed to help deal with HIV, Herpesviridae, herpes viruses, the hepatitis B and Hepatitis C, C viruses, and Influenzavirus A, influenza A and Influenzavirus ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ebola Virus Epidemic In West Africa
The 2013–2016 epidemic of Ebola virus disease, centered in West Africa, was the most widespread outbreak of the disease in history. It caused major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone. The first cases were recorded in Guinea in December 2013; the disease spread to neighbouring Liberia and Sierra Leone, with minor outbreaks occurring in Nigeria and Mali. Secondary infections of medical workers occurred in the United States and Spain. Isolated cases were recorded in Senegal, the United Kingdom and Italy. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources. It caused significant mortality, with a considerable case fatality rate. By the end of the epidemic, 28,616 people had been infected; of these, 11,310 had died, for a case-fatality rate of 40%. , the World Health Organization (WHO) and respective governments repor ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
JK-05
JK-05 is a broad-spectrum antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences. It is reported to act as an inhibitor of the viral enzyme RNA polymerase, which is essential for viral replication. In tests on mice, JK-05 was claimed to show efficacy against a range of RNA viruses, including influenza, Ebola virus, and yellow fever, as well as several arenaviruses and bunyaviruses. The chemical structure of JK-05 has not been disclosed as of October 2014, but it is claimed to be a small molecule drug with a comparatively simple structure, which should be readily amenable to synthesis scale-up for mass production if testing is successful. The drug is, however, admitted to be similar to the Japanese anti-influenza drug favipiravir, developed by Fujifilm , trading as , or simply Fuji, is a Japanese Multinational corporation, multinational Conglomerate (company), conglomerate headquartered in Tokyo, Jap ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GS-441524
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective ''in vitro'' against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it), but GS-441524 has been found to be effective treatment for FIP. It is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use. In several countries oral GS-441524 tablets (and injectable remdesivir) became legally available to vets for the treatment of FIP in cats, for example Australia, the Netherlands, and the United Kingdom. Besides remdesivir, other prodrugs include obeldesivir (Gilead Sciences, Phase III) and deuremidevir (Vigon ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FGI-106
FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus dengue virus, and the filoviruses Ebola virus and Marburg virus. See also * Brincidofovir * BCX4430 * Favipiravir * FGI-103 * FGI-104 * LJ-001 * TKM-Ebola * ZMapp References Anti–RNA virus drugs Antiviral drugs Ebola Experimental antiviral drugs Nitrogen heterocycles Heterocyclic compounds with 4 rings Dimethylamino compounds {{antiinfective-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Favipiravir
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co. It became a generic drug in 2019. Medical use Favipiravir has been approved to treat influenza in Japan. It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza. As of 2020, the probability of resistance developing appears low. Side effects There is evidence that use during pregnancy may result in harm to the baby. Teratogenic and embryotoxic effects were shown on four animal species. In one case report ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3-Deazaneplanocin A
3-Deazaneplanocin A (DZNep, C-c3Ado) is a drug which acts as both a ''S''-adenosylhomocysteine synthesis inhibitor and also a histone methyltransferase EZH2 inhibitor. Studies have shown that it has effects ''in vitro'' against a variety of different tumor cell lines. In studies on mice, the drug was also found to be effective for the treatment of Ebola virus disease, apparently interfering with the Ebola viruses ability to block interferon Interferons (IFNs, ) are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten ... production, thus restoring the ability of immune system to rid the body of ebolavirus. References {{DEFAULTSORT:Deazaneplanocin A, 3- Nucleosides Imidazopyridines Polyols Experimental drugs Cyclopentenes ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Coronavir
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co. It became a generic drug in 2019. Medical use Favipiravir has been approved to treat influenza in Japan. It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza. As of 2020, the probability of resistance developing appears low. Side effects There is evidence that use during pregnancy may result in harm to the baby. Teratogenic and embryotoxic effects were shown on four animal species. In one case report ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Brincidofovir
Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability. The most common side effects include diarrhea, nausea, vomiting, and abdominal pain. It carries an FDA-mandated Boxed warning, black box warning of an increased risk of death with extended use. Brincidofovir was approved for medical use in the United States in June 2021. Medical uses Brincidofovir is Indication (medicine), indicated for the treatment of human smallpox disease caused by the variola virus. Mechanism of action Brincidofovir is a prodrug that is composed of cidofovir Conjugation (biochemistry), conjugated with a lipid molecule. The lipid aspect of the molecule takes on the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Bemnifosbuvir
Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. Bemnifosbuvir has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages. Bemnifosbuvir's Phase III study ended early as it failed to meet its primary endpoint of symptom alleviation and did not decrease viral load. However, the drug was well-tolerated and reduced relative hospitalization risk by 71%. See also * Galidesivir * Remdesivir * Lufotrelvir * Molnupiravir * Sofosbuvir Sofosb ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
